

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[About Memorial Sloan Kettering Cancer Center & Treatment](#)

[Learn About Cancer & Treatment](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA

Connect with us

Stay Informed.

Get the latest news and updates on MSK's cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.

[Newsletter Sign Up](#)

1832 News Items found




[Bladder Cancer Therapy Enfortumab Vedotin \(Padcev\) Approved by FDA for More Patients](#)

Thursday, December 11, 2025

A powerful therapy called an antibody-drug conjugate has been approved by the FDA for more people with bladder cancer.

ARTICLE



[Antibody-Drug Conjugate for Endocrine-Refractory and Chemotherapy Naive HR+, HER2- Breast Cancer](#)

Wednesday, December 10, 2025

Read about an antibody-drug conjugate treatment for HR+, HER2- breast cancer.



[Diets for MGUS, Smoldering Myeloma, and Multiple Myeloma: Q&A With MSK Cancer and Nutrition Experts](#)

Monday, December 8, 2025

Learn how eating a plant-based diet may prevent MGUS and smoldering myeloma from developing into multiple myeloma, according to MSK research.




[MSK Research Reveals Connection Between Diet and Cancer](#)

Monday, December 8, 2025

Learn more about how a clinical trial at MSK revealed important connections between the foods we eat and our cancer risk.

CLINICAL UPDATE



[CAR T Cell Therapy for Light Chain \(AL\) Amyloidosis Achieves Strong Results](#)

Sunday, December 7, 2025

Read about a CAR T cell therapy that appears effective against light chain (AL) amyloidosis.

ARTICLE



[New Extramedullary Myeloma Treatment With Bispecific Antibodies Improves Survival Dramatically](#)

Sunday, December 7, 2025

Read about a new treatment combining bispecific antibodies that is effective against extramedullary myeloma.



[New Treatment for Relapsed Follicular Lymphoma Approved by FDA After MSK-Led Clinical Trial](#)

Sunday, December 7, 2025

A phase 3 trial led by MSK showed that adding epcoritamab to traditional treatment for follicular lymphoma benefits patients. Epcoritamab received FDA approval based on the findings.



[Cancer Care Worth Traveling For: Why People Come to MSK From Across the Country](#)

Thursday, December 4, 2025

Learn why over 5,000 people a year travel more than 150 miles to MSK for cancer care, including resources for the specific needs of traveling patients and their loved ones.



[Cancer Benefits and Risks From Ozempic, Wegovy, and Other Weight Loss Drugs](#)

Wednesday, December 3, 2025

Learn what Zepbound, Wegovy, Ozempic and other weight loss drugs mean for cancer risk and treatment, from an expert at MSK.

Q&A



[Meet Omar Abdel-Wahab: A 2025 Paul Marks Prize Recipient](#)

Monday, December 1, 2025

A leader in developing better treatments for a range of blood cancers, Dr. Omar Abdel-Wahab is only the second person from MSK to receive the Paul Marks Prize for Cancer Research.

[Load More](#)

PREVIOUS

[Newsroom](#)

NEXT

[Cancer Vaccine Could Prevent Neuroblastoma
From Returning After Antibody Treatment](#)

© 2025 Memorial Sloan Kettering Cancer Center